Daniel Wasmuth

Title: The Innovations of Daniel Wasmuth

Introduction

Daniel Wasmuth is an accomplished inventor based in Bättwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the area of bioavailability of renin inhibitors. His work is crucial for developing effective treatments for conditions that require the modulation of renin activity.

Latest Patents

Daniel Wasmuth holds a patent for "Methods for improving bioavailability of a renin inhibitor." This invention provides a method for enhancing the bioavailability of a renin inhibitor, specifically a δ-amino-γ-hydroxy-ω-aryl-alkanoic acid derivative. The method involves co-administering a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, along with an efflux protein inhibitor to a mammal, particularly a human in need of such treatment. He has 1 patent to his name.

Career Highlights

Daniel is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to work on innovative solutions that address critical health challenges. His expertise in pharmacology and drug formulation has positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

Throughout his career, Daniel has collaborated with notable colleagues, including Isabel Ottinger and Gerhard Gross. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Daniel Wasmuth's contributions to the field of pharmaceuticals, particularly through his patent on improving the bioavailability of renin inhibitors, highlight his role as an influential inventor. His work continues to impact the development of effective treatments in healthcare.